Journal: Cell Reports Medicine
Article Title: Targeting severe acidity for tumor-activatable Interleukin-2 therapy
doi: 10.1016/j.xcrm.2025.102572
Figure Lengend Snippet: pH-responsive blocking and restoration of IL-2 receptor binding by UPS 5.3 (A) Schematic of the experimental design to assess the intrinsic interaction between UPS 5.3 micelles and proteins. (B) FPLC chromatograms showing individual proteins or UPS 5.3 /protein mixtures. (C) Molecular docking model of the DBA dimer (blue) with IL-2, highlighting predicted interaction sites. (D–F) Biolayer interferometry analysis of IL-2-Fc binding to IL-2Rα, IL-2Rβ, and IL-2Rγ, with and without UPS 5.3 NP encapsulation. (G) Schematic illustrating ex vivo assessment of IL-2-Fc binding to immune cells from various organs. (H) Quantification of IL-2-Fc binding to lymphocytes isolated from liver, lung, spleen, and tumor ( n = 5). Data are presented as mean ± SEM. See also and .
Article Snippet: InVivoMAb anti-mouse CD25 (IL-2Rα) , BioXcell , Cat# BE0012 RRID: AB_1107619.
Techniques: Blocking Assay, Binding Assay, Encapsulation, Ex Vivo, Isolation